A PHASE 3, 12-MONTH, OPEN-LABEL STUDY OF LASMIDITAN IN PEDIATRIC PATIENTS WITH MIGRAINE TREATMENT OF MIGRAINE- PIONEER-PEDS2
- Registry ID
- H8H-MC-LAHW
- Source registry
- HEALTH_CANADA
- Status
- Ongoing
- Phase
- PHASE3
- Study type
- INTERVENTIONAL
- Sponsor
- ELI LILLY CANADA INC
- Start date
- 2020-12-10
- Last update
- 2020-06-11
Conditions
Related clinical trials
- CANNABIS FOR THE PROPHYLACTIC TREATMENT OF MIGRAINE: A RANDOMIZED
DOUBLE-BLIND PLACEBO-CONTROLLED CLINICAL TRIAL
- AN INTERVENTIONAL EFFICACY AND SAFETY, PHASE 3, DOUBLE-BLIND, PARALLEL-GROUP STUDY TO INVESTIGATE INTERMITTENT PREVENTION OF MENSTRUAL MIGRAINE WITH RIMEGEPANT COMPARED WITH PLACEBO IN WOMEN PARTICIPANTS 18 TO 45 YEARS OF AGE
- EPTINEZUMAB AS AN ADJUNCT TO STANDARD OF CARE FOR MIGRANE IN AN ACUTE EMERGENCY CONTEXT
(MIGRAINE ERASE STUDY)
- A MULTICENTER, OPEN-LABEL, EXTENSION STUDY TO EVALUATE THE LONG-TERM SAFETY AND TOLERABILITY OF ATOGEPANT IN PEDIATRIC SUBJECTS 6 TO 17 YEARS OF AGE WITH MIGRAINE
- PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, GROUP SEQUENTIAL, PLACEBO-CONTROLLED STUDY TO ASSESS EFFICACY AND SAFETY OF RIMEGEPANT FOR THE TREATMENT OF MIGRAINE (WITH OR WITHOUT AURA) IN CHILDREN AND ADOLESCENTS FROM = 6 TO <18 YEARS OF AGE
- PEDIATRIC OPTIONS FOR MIGRAINE RELIEF: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF LASMIDITAN FOR ACUTE TREATMENT OF MIGRAINE: PIONEER-PEDS1
View on source registry